Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. (HUMA) has had its Redeemable Warrants removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. These warrants were each exercisable for one share of common stock at an exercise price of $11.50. Nasdaq states that it has complied with its own rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing, and that Humacyte has complied with the Exchange’s rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal. Nasdaq, through an authorized officer, certifies that it has reasonable grounds to believe it meets all requirements for filing Form 25.
Humacyte, Inc. (HUMA) director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock in an open market or private transaction on August 20, 2026 at a price of $0.693 per share. Following this transaction, he directly owns 40,000 shares of Humacyte common stock.
Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased Humacyte common stock in the open market. On 2026-08-17, he bought 30,000 shares at a weighted average price of about $0.594 per share, resulting in direct holdings of 30,000 shares.
Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG filed Amendment No. 11 updating their ownership in Humacyte, Inc. common stock. They report beneficial ownership of 13,603,235 shares, representing 4.9% of Humacyte’s outstanding voting shares, based on 277,798,105 shares outstanding as of August 10, 2026.
The filing details a series of open-market sales between August 10 and August 17, 2026 under a Rule 10b5‑1 trading plan with Citigroup Global Markets Inc., after which the reporting persons ceased to beneficially own more than five percent of Humacyte’s common stock. It also notes that Cassie McLean became President and CEO of FMCH and a Management Board member and CEO of FME AG’s Care Delivery segment effective August 1, 2026, succeeding Craig Cordola following his retirement.
Humacyte, Inc. reported modest commercialization progress and continued heavy losses for the six months ended June 30, 2026. Total revenue was $0.9 million, up slightly from $0.8 million a year earlier, driven by Symvess product revenue of $0.9 million.
Operating expenses remained high, with research and development of $37.6 million and general and administrative of $16.0 million, leading to an operating loss of $55.9 million and a net loss of $54.4 million for the six-month period. Net cash used in operating activities was $47.2 million. The company had cash and cash equivalents of $79.9 million and an accumulated deficit of $781.3 million as of June 30, 2026.
Humacyte raised capital through a $18.3 million March 2026 registered direct equity offering, a $53.8 million June 2026 underwritten public offering, and $4.6 million of ATM sales, and has a $40 million term loan outstanding plus remaining capacity under a $50 million equity line. Management states that current resources are insufficient to fund operations for 12 months without additional cash generation or financing, and discloses substantial doubt about its ability to continue as a going concern.
Humacyte, Inc. reported second quarter 2026 results, highlighting clinical and commercial progress alongside continued losses. For the quarter ended June 30, 2026, total revenue was $406,000, up from $301,000 a year earlier, driven by Symvess product revenue of $0.4 million versus $0.1 million in 2025.
Loss from operations was $27.0 million, with a net loss of $36.8 million compared with a net loss of $37.7 million in the prior-year quarter. For the first six months of 2026, the company recorded a net loss of $54.4 million versus net income of $1.5 million in the first half of 2025.
Humacyte ended June 30, 2026 with $79.9 million in cash and cash equivalents, up from $50.5 million at December 31, 2025, and stockholders’ equity of $31.3 million, up from $3.1 million. The company reported breakthrough Phase 3 results for its acellular tissue engineered vessel in dialysis access, plans a supplemental BLA filing in the second half of 2026, and is preparing a Phase 2a CABG study under an accepted IND.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price closed below the $1.00 per share minimum for 30 consecutive business days ended July 30, 2026, violating Nasdaq Listing Rule 5450(a)(1).
Under Nasdaq Listing Rule 5810(c)(3)(A), Humacyte has 180 calendar days, until January 27, 2027, to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days. The notice has no immediate effect on the Nasdaq Global Select Market listing, trading symbol HUMA, or on business operations, while the company monitors its stock price and evaluates options.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Humacyte Inc. common stock. BlackRock reports beneficial ownership of 4,092,430 shares of common stock, representing 1.5% of the outstanding class.
BlackRock has sole voting power and sole dispositive power over all 4,092,430 shares and no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no individual person’s interest exceeds 5% of Humacyte’s total outstanding common shares.
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG report beneficial ownership of 18,312,735 shares of Humacyte, Inc. common stock, representing 6.8% of the outstanding class, all held with shared voting and dispositive power.
As part of FME AG’s FME Reignite strategy, the companies have decided to reduce their Humacyte stake. On July 10, 2026 FMCH entered into a Rule 10b5-1 trading plan with Citigroup Global Markets Inc. to use reasonable best efforts to sell up to 5,000,000 Humacyte shares between the end of the mandatory 30-day cooling-off period and October 31, 2026, subject to volume and other limits. Completion of these sales would lower their beneficial ownership below 5%, after which further sales would no longer be reportable under Section 13(d). FMCH has also instructed its Humacyte board observer to stop attending meetings and receiving confidential materials.
Humacyte, Inc. Schedule 13G disclosure by Davidson Kempner-affiliated reporting persons stating pooled beneficial ownership of Common Stock totaling 12,787,073 shares (reported as 4.74% of the class). The filing ties percentages to 269,638,156 shares outstanding as reported in the Company's Prospectus filed June 11, 2026.
The statement lists related entities (M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value, Davidson Kempner Capital Management LP) and identifies Anthony A. Yoseloff as responsible for voting and investment decisions. The filing classifies the position as ownership of 5% or less for some reporting persons and provides shared voting and dispositive power figures for each entity.